Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon*, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS).

Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). The Généthon-sponsored trial will be performed both in France (led by Professors Alain Fischer (1) and Marina Cavazzana-Calvo (2) at Necker Children’s Hospital, Paris) and in the UK (led by Professor Adrian Thrasher at London’s Great Ormond Street Hospital). With just a few days to go to Rare Disease Day 2010 (February 28th, with a focus on “Bridging Patients and Researchers”), initiation of this trial marks a new step towards curing rare diseases with innovative biotherapies.

Wiskott Aldrich syndrome (WAS) is a severe, X-linked immunodeficiency which results in hemorrhage, recurrent infection and eczema. It is almost always fatal in affected children. Although a bone marrow transplant can reestablish the patient’s immune system, this operation requires a compatible donor and carries a non-negligible risk of failure. Gene therapy (which has already enabled the treatment of other hereditary immune deficits) therefore represents a major source of hope for patients waiting for therapy.

The forthcoming clinical trial is the end result of research initiated in 2002 by Anne Galy’s group (UMR951) (3) in the Généthon laboratory. The lab’s researchers have developed an ex vivo approach that uses an HIV-derived lentiviral vector to transfer genes into autologous CD34+ hematopoietic stem cells from the patient. Généthon has developed, produced and quality-controlled the trial’s batches of gene-based medicines under GMP conditions.

The trial also demonstrates the extent of the AFM lab’s know-how, ranging from preclinical research and the GMP production of gene-based drugs through to trial logistics and regulatory approval.

“This trial is enabling the Généthon laboratory (funded almost exclusively by donations from France’s annual Telethon) to demonstrates its world-class expertise in the production of gene-based medicines and the preparation and implementation of clinical trials. It confirms Généthon’s ability to become a major international player in demonstrating the efficacy of gene therapy for rare diseases” emphasized AFM and Généthon President Laurence Tiennot-Herment.